Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

NCT01449357 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Trial never initiated

Conditions

Interventions

Sponsor

Genmab